Showing results (211-220 of 253) with videos related to

Sort By:
Pageof 26
Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyDonald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.
Hypertension (Dallas, Tex. : 1979)|March 2, 2005
PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whitesGitte Andersen, Lise Wegner, Dorit Packert Jensen, et al.
Diabetes, Obesity & Metabolism|February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathyHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism|April 1, 2018
Baseline characteristics and enrichment results from the SONAR trialHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism|December 17, 2016
Comparison of exposure response relationship of atrasentan between North American and Asian populationsHiddo J L Heerspink, Hirofumi Makino, Dennis Andress, et al.
Clinical Pharmacology and Therapeutics|December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney DiseaseJeroen V Koomen, Jasper Stevens, George Bakris, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized TrialSimke W Waijer, Ron T Gansevoort, George L Bakris, et al.
Journal of the American Society of Nephrology : JASN|February 13, 2009
Expression, localization, and function of the thioredoxin system in diabetic nephropathyAndrew Advani, Richard E Gilbert, Kerri Thai, et al.
Pageof 26